The insulin pens, syringes, pumps and injectors devices and equipment market consist of sales of insulin pens, syringes, pumps and injectors and related services. Insulin pens are reusable pen-like tools used to inject desired a dose of insulin into the blood of a diabetic patient. Insulin helps to ensure that glucose levels in the patient’s blood are appropriate. Insulin syringes are the reusable devices used to inject insulin which is specifically made for self-administration. Insulin pumps and injectors are the devices which are used to deliver insulin continuously throughout the day to the diabetic patient and maintain blood glucose levels. The global insulin pens, syringes, pumps and injectors market is expected to grow from $16.1 billion in 2019 to $17.8 billion in 2020 at a compound annual growth rate (CAGR) of 10.7%. The growth is mainly due to the COVID-19 outbreak as people with diabetes are at increased risk of serious illness from COVID-19. The market is then expected to grow at a CAGR of 7.9% from 2021 and reach $21.9 billion in 2023. Diabetic care devices are increasingly being used by care providers and patients (self-monitor) to frequently check the blood glucose levels. FDA issued guidance to expand the availability and capability of non-invasive remote monitoring devices including continuous glucose monitors (CGM) during the COVID-19 pandemic. However, the growth is not as significant as expected due to the demand and supply gaps. North America was the largest region in the insulin pens, syringes, pumps and injectors market in 2021. The insulin pens, syringes, pumps and injectors market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023. An increase in the prevalence of diabetes globally is driving the growth of insulin pens, syringes, pumps, and injectors market. Increase in number of people suffering from obesity, unhealthy eating habits, physical inactivity and increasing geriatric population are some of the key factors which are leading to the increase in the global prevalence of diabetes. According to the US Centers for Disease Control and Prevention (CDC) in 2016, around 29 million people in the U.S. were suffering from diabetes. Also, according to the International Diabetes Federation, in 2017, globally approximately 425 million adults were living with diabetes; by 2045, this number would rise by 48% to 629 million, driving the insulin pens, syringes, pumps and injectors market. Resistance towards self-injection by patients is restraining the insulin pens, syringes, pumps and injectors market. The fear of injections causes anxiety in some patients thus causing them to avoid the use of insulin injections and being inconsistent in their insulin uptake. In 2015, according to a report by National Center for Biotechnology Information (NCBI), anxiety about and the fear of injection-associated pain has been estimated to affect approximately 30%–50% of patients, before the initiation of diabetes education interventions. The report also stated that close to 28% of patients were unwilling to initiate insulin therapy, if prescribed, because they were not confident about handling the injections and the anticipated needle pain due to self-injection. This resistance for self-injection due to the fear of needles is hampering the growth of the market. Many companies are focusing on technological advancements in insulin delivery systems to deliver insulin effectively and safely. For instance, on June 2018, the US Food and Drug Administration approved MiniMed 670G hybrid closed looped system for curing diabetic individuals aged between 7-13 years of age. This is a diabetes management device that automatically monitors glucose and provides appropriate level insulin doses needed. It requires little or no input from the user. Similarly, on February 2019, FDA also approved Tandem Diabetes Care t: Slim X2 insulin pump. This pump uses interoperable technology that allows patients to customize their diabetes management devices according to their preferences. These devices contain of automated insulin dosing systems, continuous glucose monitors, blood glucose meters or other electronic devices. The insulin pens, syringes, pumps and injectors devices and equipment market are regulated by authorities such as the US FDA and European Medicines Agency. For instance, FDA’s Title 21 of the Code of Federal Regulations (CFR) provide guidelines for proper labelling of medical devices such as food, drugs, cosmetics and other medical devices, which manufacturers of these devices must comply and adhere to. The FDA also provides strict label warnings prohibiting the sharing of insulin injectable medicines, to avoid infections in patients which are caused by the sharing of these insulin devices. On August 2018, Novo Nordisk acquired Ziylo for more than $800 million. Ziylo, founded in 2014 is a Bristol-based company that manufactures glucose-responsive insulins. This acquisition helped Novo Nordisk to use Ziylo’s new technology to develop the glucose-responsive insulins, for safe and effective delivery of insulin to the patients.

The pain management devices and therapies manage chronic and critical pain in patients suffering from various conditions, such as cancer and neurological disorder. These are mainly used for spinal cord stimulation, sacral nerve stimulators, and deep brain stimulation. The main types of pain management devices and therapies are electrical stimulators, ablation devices, neurostimulators, and analgesic pumps. The various electrical stimulation devices include transcutaneous electrical nerve stimulation (TENS) devices, neuromuscular electrical stimulation (NMES/EMS) devices, combination devices, electrotherapy devices, and TNS, ablation devices include radiofrequency ablation devices, cryoablation devices and neurostimulation devices including spinal cord stimulation (SCS) devices, deep brain stimulation devices, vagus nerve stimulation devices, and sacral nerve stimulation devices. The analgesic infusion pumps covered in this market are intrathecal infusion pumps, and external infusion pumps that are used for neuropathic pain, cancer pain, facial & migraine pain, musculoskeletal pain, and trauma applications. The pain management devices and therapies market research report is one of a series of new reports from The Business Research Company that provides pain management devices and therapies market statistics, including pain management devices and therapies industry global market size, regional shares, competitors with a pain management devices and therapies market share, detailed pain management devices and therapies market segments, market trends and opportunities, and any further data you may need to thrive in the pain management devices and therapies industry. This pain management devices and therapies market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global pain management devices and therapies market grew from $4.01 billion in 2022 to $4.38 billion in 2023 at a compound annual growth rate (CAGR) of 9.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pain management devices and therapies market is expected to grow from $6.1 billion in 2027 at a CAGR of 8.6%. An increase in demand for pain management devices due rise in chronic diseases is driving the growth of the pain management devices and therapies market. Chronic diseases such as cancer, heart stroke often lead to unbearable pain in patients and thus creating a demand for pain management drugs and therapies. Chronic diseases persist over a long period and deteriorate the health of the patient. As reported in an article by the Brazilian Journal of Nephrology, around 60% of patients with chronic kidney disease reported pain of any kind of intensity, which required pain management drugs. Similarly, according to a report in the 'US National Library of Medicine, approximately 45% or 133 million of all Americans suffered from at least one chronic disease. It is also stated that more than two-thirds of all deaths are due to one of the chronic illnesses, which included coronary heart sickness, cancer, stroke, persistent obstructive pulmonary disease, and diabetes. This rise in chronic diseases is increasing the demand for pain management devices and therapies and driving the market. The availability of other alternatives to manage pain is restraining the growth of the pain management devices and therapies market. Alternatives treatment methods such as acupuncture, Marijuana treatment, dietary supplements, vitamins, etc. are being used instead of expensive pain relief devices and equipment. These alternative treatments may help with pain from bad backs, osteoarthritis, and headaches. For instance, the use of acupuncture works well for pain caused by many conditions, including fibromyalgia, osteoarthritis, back injuries, and sports injuries. Acupuncture is an ancient Chinese treatment that involves inserting thin pins through a person's skin at specific points on the body. Acupuncture comes with no prominent side effects and costs less compared to devices and equipment used to control pain. This rise in the use of alternative treatment methods is affecting the sales of pain management devices and therapies, and limiting the growth of the market. Companies in the pain management devices and therapies industry are focusing on the use of advanced technologies to cure chronic and acute pain without the use of any opioids (drugs). Special pain relief wearable devices are being developed by several companies that can be controlled manually or through a smartphone. These devices work by gathering neural pulses from the brain which triggers the release of the body's natural pain blocker. Thus, the devices electrically stimulate the nervous system and increase the body's resistance to pain. Companies such as NeuroMetrix, Sana, Oska wellness have introduced various types of wearable devices, ranging from a wearable mask, knee band, wrist band, etc. FDA has approved these devices as OTC (over-the-counter), which can be bought without a prescription. USFDA has defined the Pain Management Devices in section 882 under the medical devices market, under subchapter-H in Code of Federal Regulations (Title 21). Under these regulations, FDA requires the device manufacturers to register and list their devices with FDA and to follow general control requirements related to labeling, packaging, performance standards, and pre-market approval. To apply for premarket approval by FDA, the manufacturer is required to submit a premarket approval application that should include evidence providing reasonable assurance that the device is safe and effective. As per the FDA rule, the manufacturer can also submit a 510(k) notification demonstrating that the device is substantially equivalent to a device already on the market (a predicate device) that does not require a PMA. Major players in the pain management devices and therapies market are Abbott Laboratories, AstraZeneca, Pfizer, Boston Scientific Corporation, GlaxoSmithKline PLC., Teva Pharmaceutical Industries Ltd., Medtronic PLC., Novartis AG, Baxter International Inc., and Johnson & Johnson. North America was the largest region in the pain management devices and therapies market in 2022. Western Europe was the second largest region in the global pain management devices and therapies market report. The regions covered in the global pain management devices and therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the pain management devices and therapies market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The pain management devices and therapies market consists of sales of physical therapy, massage, acupuncture, osteopathic manipulative treatment (OMT) and chiropractic adjustments. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pain management devices and therapies market is segmented - 1) By Type: Electrical Stimulators, Ablation Devices, Neurostimulators, Analgesic Pumps 2) By Application: Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, Trauma 3) By Electrical Stimulation Devices: Transcutaneous Electrical Nerve Stimulation (TENS) Devices, Neuromuscular Electrical Stimulation (NMES/EMS) Devices, Combination Devices, Electrotherapy Devices, TNS 4) By Ablation Devices: Radiofrequency Ablation Devices, Cryoablation Devices 5) By Analgesic Infusion Pumps: Intrathecal Infusion Pumps, External Infusion Pumps 6) By Neurostimulation Devices: Spinal Cord Stimulation (SCS) Devices, Deep Brain Stimulation Devices, Vagus Nerve Stimulation Devices, Sacral Nerve Stimulation Devices

Implantable drug delivery devices are drug delivery systems implanted under the skin that transmit drugs into the bloodstream from a reservoir. These devices facilitate site specific drug delivery and require smaller doses, thereby minimising side effects. The main products of implantable drug delivery devices is contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bioabsorbable stents, intraocular stents, infusion pumps, and others. Spinal implants are devices that are used by surgeons while performing surgery to treat deformity, stabilise and strengthen the spine, and facilitate fusion. The technologies involved are diffusion, osmosis, magnetic, and others. The various applications involved are contraception, ophthalmology, cardiovascular, diabetes, oncology, autoimmune diseases, and others. The implantable drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides implantable drug delivery devices market statistics, including implantable drug delivery devices industry global market size, regional shares, competitors with a implantable drug delivery devices market share, detailed implantable drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the implantable drug delivery devices industry. This implantable drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global implantable drug delivery devices market grew from $18.35 billion in 2022 to $19.58 billion in 2023 at a compound annual growth rate (CAGR) of 6.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The implantable drug delivery devices market is expected to grow from $26 billion in 2027 at a CAGR of 7.3%. The rise in the incidence of target diseases such as diabetic retinopathy, cancer, cardiovascular diseases, and other chronic diseases is expected to drive the implantable drug delivery devices market. According to the International Diabetes Federation (IDF), the global prevalence of diabetic retinopathy was one in three in 2020. Implantable drug delivery devices are used for site-specific drug administration where the drug is most needed, such as Gliadel® wafer as an implant used in the treatment of brain tumors, Lupron depot for the treatment of prostate cancer. Hence, the site-specific drug administration nature of implantable drug devices, which help in the treatment of target diseases, is driving the implantable drug delivery devices market. The rising number of product recalls and lawsuits associated with implantable drug delivery devices is expected to hinder the market. In the past few years, there had been an increase in product recalls and lawsuits connected with these devices. For instance, in June 2022, Medtronic plc recalled Cobalt XT, Cobalt, and Crome Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) for the reasons of reports of devices with a short circuit protection (SCP) alert resulting in reduced-energy electric shock delivery, instead of delivering a second phase of high voltage therapy. This may result in failure of device and irregular heartbeat which can lead to more serious issues. Therefore, the rising number of product recalls and lawsuits concerning implantable drug delivery devices is expected to hinder the growth of the market. Companies and researchers are focusing on developing 3D implantable drug delivery devices. 3D printed titanium transcutaneous ports are implanted behind the patient's ear, allowing healthcare professionals to access the catheters. For instance, in February 2020, Renishaw and Herantis Pharma announced the award-winning device, which received positive results in phase 2 trials, that consists of up to four catheters implanted in the relevant brain areas. Researchers at King Abdullah University of Science and Technology have introduced a miniaturized drug delivery system suitable for in-vivo biomedical applications. The system consists of an electrolytic pump, which operates a micro bellows membrane as an actuator for delivery through microneedles. A two-photon 3D printing technique was used to make a reservoir equipped with a microneedle. In February 2022, Second Sight Medical Products, a California-based manufacturer of prosthetic devices, merged with Nano Precision Medical. The companies would collaborate to develop drug delivery medical implants.Nano Precision Medical is a US-based developer of NanoPortal drug implant technology. Major players in the implantable drug delivery devices market are Allergan Inc., Bayer HealthCare, Medtronic Inc., Nucletron, Boston Scientific Corporation, Abbott Laboratories, Bausch and Lomb Inc., Merck, Genetech Inc., and Psivida. North America was the largest region in the implantable drug delivery devices market in 2022. Asia-Pacific was the second-largest region in the global implantable drug delivery devices market report. The regions covered in the global implantable drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the implantable drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The implantable drug delivery devices market consists of sales of contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bio-absorbable stents, intraocular stents, infusion pumps, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global implantable drug delivery devices market is segmented - 1) By Product: Contraceptive Implants, Spinal Implants, Brachytherapy Seeds, Drug-Eluting Stents, Bio-absorbable Stents, Intraocular Stents, Infusion Pumps, Other Applications 2) By Technology: Diffusion, Osmotic, Magnetic, Other Technologies 3) By Application: Contraception, Ophthalmology, Cardiovascular, Diabetes, Oncology, Autoimmune Diseases, Other Applications

Intravenous infusion pumps are medical devices used for controlled delivery of drugs into the patient's body. The intravenous infusion pumps market covered in this report is segmented by product into the volumetric, syringe, enteral, ambulatory, IV disposables, and others. A syringe is a reciprocating pump used to deliver drugs and consists of a plunger. It is also segmented by application into chemotherapy, diabetes, gastroenterology, analgesia/pain management, pediatrics/neonatology, haematology, others, and by end-user into hospitals, ambulatory surgical centers, cancer treatment centers, specialty clinics, and others. The intravenous infusion pumps market research report is one of a series of new reports from The Business Research Company that provides intravenous infusion pumps market statistics, including intravenous infusion pumps industry global market size, regional shares, competitors with a intravenous infusion pumps market share, detailed intravenous infusion pumps market segments, market trends and opportunities, and any further data you may need to thrive in the intravenous infusion pumps industry. This intravenous infusion pumps market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global intravenous infusion pumps market grew from $5.32 billion in 2022 to $5.68 billion in 2023 at a compound annual growth rate (CAGR) of 6.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The intravenous infusion pumps market is expected to grow from $7.6 billion in 2027 at a CAGR of 7.5%. The rise in the prevalence of people with chronic pain, cancer, and diabetes is a significant driver of the demand for intravenous infusion pumps, as these pumps are commonly used to deliver pharmaceutical drugs during the treatment of these diseases. Chronic illnesses and disorders are on the rise around the world, which can be attributed to an aging population and shifts in social behavior that lead to a gradual increase of these widespread and expensive long-term medical issues. Infusion pumps are used to transfer regulated doses of nutrients or drugs into a patient's body, such as chemotherapy medicines, pain relievers, antibiotics, insulin, or other hormones. The prevalence of chronic diseases is expected to increase by 57% by 2020, according to the World Health Organization. Therefore, the rise in the prevalence of chronic diseases is expected to drive the growth of the intravenous infusion pumps market. The high cost of intravenous infusion pumps is a key factor hampering the growth of the intravenous infusion pumps market. The cost of medication therapies is expected to double when the intravenous infusion pumps in hospitals and pharmacies are networked, as they are pre-programmed with set limits to avoid intoxication or overdoses. For example, the cost of the syringe pump ranges from $2,380 to $5,982. Besides, the pump-hardware support contracts vary between $150 to $250 per pump. Therefore, the high cost of intravenous infusion pumps, which increases the cost of drug therapies, is expected to hinder the market growth for intravenous infusion pumps. The growing technological improvement is a major trend gaining popularity in the intravenous infusion pumps market. Technological advances in infusion pumps have changed medical care in hospitals and allowed patients to inject fluids on an outpatient basis or in a home setting, allowing them to seek treatment while living their daily lives, through the use of smart intravenous infusion pumps. These smart intravenous infusion pumps help prevent medication errors and reduce patient harm. Some of the major companies investing in smart intravenous pumps include Fresenius Kabi, Q-Core Medical, Becton Dickinson, Micrel Medical Devices, and Baxter International. In another instance, vTitan, a Chennai-based healthcare company, announced the launch of the next generation of Syringe Infusion Pumps, which are used for critical care in hospitals and homes for reliable and safe infusion of drugs. In March 2022, Fresenius Kabi, a Germany-based pharmaceuticals company, acquired Ivenix for $240 million in upfront payments and milestone payments. The acquisition would help the company to improve its offerings and help it better serve the customer’s needs. Ivenix is a US-based manufacturer of infusion pumps. Major players in the intravenous infusion pumps market are B. Braun Melsungen AG, Baxter International, Medtronic, Fresenius Kabi, Smiths Medical Inc., Becton Dickinson and Company, Terumo Corporation, F. Hoffmann-La Roche Ltd., ICU Medical Inc., and IRadimed Corporation. North America was the largest region in the intravenous infusion pumps market in 2022. Western Europe was the second-largest region in the global intravenous infusion pumps market. The regions covered in the global intravenous infusion pumps market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the intravenous infusion pumps market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The intravenous infusion pumps market consists of sales of volumetric infusion pumps, syringe infusion pumps, and patient controlled analgesia infusion pumps. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global intravenous infusion pumps market is segmented - 1) By Product: Volumetric, Syringe, Enteral, Ambulatory, IV Disposables, Other Products 2) By End-User: Hospitals, Ambulatory Surgical Centers, Cancer Treatment Centers, Specialty Clinics, Other End Users 3) By Application: Chemotherapy, Diabetes, Gastroenterology, Analgesia/Pain Management, Pediatrics/Neonatology, Haematology, Other Applications

Implantable infusion pumps are drug delivery systems implanted in the patients body that pump the medication into the blood stream in a controlled manner. The implantable infusion pumps market is segmented by type into patient-controlled analgesia (PCA) pumps, enteral pumps, insulin pumps, elastomeric pumps, syringe pumps, and others. The insulin pump is a small device that is put beneath the skin during the operation to deliver insulin in diabetic patients. The various applications of implantable infusion pumps are oncology, pediatrics/neonatology, gastroenterology, hematology, diabetes, and others that are used by hospitals, ambulatory surgical centers, and specialty clinics. The implantable infusion pumps market research report is one of a series of new reports from The Business Research Company that provides implantable infusion pumps market statistics, including implantable infusion pumps industry global market size, regional shares, competitors with a implantable infusion pumps market share, detailed implantable infusion pumps market segments, market trends and opportunities, and any further data you may need to thrive in the implantable infusion pumps industry. This implantable infusion pumps market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global implantable infusion pumps market grew from $18.26 billion in 2022 to $19.14 billion in 2023 at a compound annual growth rate (CAGR) of 4.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The implantable infusion pumps market is expected to grow from $23.12 billion in 2027 at a CAGR of 4.8%. The increased prevalence of people with chronic pain, cancer, and diabetes is expected to drive the demand for implantable infusion pumps, as these pumps are commonly used to deliver pharmaceutical drugs during the treatment of these diseases. Chronic illnesses and disorders are on the rise around the world, as the aging population and shifts in social behavior lead to a gradual increase in these diseases. In diseases such as chronic arachnoiditis, which is a condition where one of the membranes surrounding the spinal cord swells, implantable infusion pumps deliver lower dosages of drugs and tend to provide more efficient pain relief. The prevalence of chronic diseases is expected to increase by 57% by 2020, according to the World Health Organization. Therefore, the rise in the prevalence of chronic diseases is expected to drive the growth of the implantable infusion pumps market. The safety concern regarding implantable infusion pumps is a key factor hampering the growth of the implantable infusion pumps market. The magnetic resonance (MR) system can be useful in the diagnosis of a wide range of conditions and diseases, but the MRI setting poses a risk factor for patients with implantable infusion pumps. An MRI examination can influence the programming or functionality of an infusion pump, even if specific requirements have been met. The US food and drug administration received evidence of significant adverse effects including harm to the patient and death associated with the use of implantable infusion pumps in the MR field. Therefore, the safety concerns regarding implantable infusion pumps are expected to limit the growth of the implantable infusion pumps market. Companies in the implantable infusion pump market are increasingly focusing on developing smart infusion pumps. The use of wireless technology in health monitoring devices is increasing, which enhances the ease of usage, connectivity, and data analysis. The integration of wireless technology allows the transfer of data from the device to a smartphone or a wireless device through Bluetooth or cellular connection for data processing and then to display the results, which can be used for further study and to check the health condition of the individual. Software platforms are being developed that allow patient monitoring and reduce human error. In September 2021, Medtronic, a US-based medical device company, acquired implanted infusion pump technology from Alfred E. Mann Foundation. The acquisition is aimed to improve insulin delivery in people with type-1 diabetes. Alfred E. Mann Foundation is a US-based scientific research foundation developing implantable infusion pumps and other medical devices. Major players in the implantable infusion pumps market are Medtronic, Boston Scientific Corporation, Nevro Corporation, Cyberonics, Baxter, B=. Braun Melsungen AG, Fresenius Kabi AG, Smiths Medical, Terumo Corporation, and Neuropace. North America was the largest region in the implantable infusion pumps market in 2022. Asia-Pacific was the second-largest region in the global implantable infusion pumps market. The regions covered in the global implantable infusion pumps market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the implantable infusion pumps market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The implantable infusion pumps market consists of sales of instruments such as patient-controlled analgesia (PCA) pumps, enteral pumps, insulin pumps, elastomeric pumps, syringe pumps, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global implantable infusion pumps market is segmented - 1) By Type: Patient-Controlled Analgesia (PCA) Pumps, Enteral Pumps, Insulin Pumps, Elastomeric Pumps, Syringe Pumps, Other Types 2) By Applications: Oncology, Pediatrics/Neonatology, Gastroenterology, Hematology, Diabetes, Other Applications 3) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics

Diabetes care devices are used to monitor and control blood glucose levels in diabetic patients. The main types of diabetes care devices are blood glucose test strips, insulin pens, syringes, pumps and injectors, lancing devices and equipment, continuous glucose monitoring devices and equipment, and blood glucose meters. Insulin pens are injection devices with a needle that delivers insulin into the subcutaneous tissue. The type of expenditures is public and private. The products used are instruments/equipment and disposables. The various end-users are hospitals and clinics, diagnostic laboratories, and others. The diabetes care devices market research report is one of a series of new reports from The Business Research Company that provides diabetes care devices market statistics, including diabetes care devices industry global market size, regional shares, competitors with a diabetes care devices market share, detailed diabetes care devices market segments, market trends and opportunities, and any further data you may need to thrive in the diabetes care devices industry. This diabetes care devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global diabetes care devices market grew from $58.63 billion in 2022 to $62.94 billion in 2023 at a compound annual growth rate (CAGR) of 7.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The diabetes care devices market is expected to grow to $80.06 billion in 2027 at a CAGR of 6.2%. Busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as diabetes. Long working hours, limited physical activity, and unhealthy eating and drinking habits are major causes of diabetes. For instance, according to WHO data 2021, more than 95% of people with diabetes have type 2 diabetes. According to a World Health Organization (WHO) report, 74% of men and 64% of women in the UK, for instance, are expected to be overweight by 2030. These factors are expected to increase the patient pool of diabetes. For instance, according to IDF data 2021, nearly 537 million adults (20-79 years) are living with diabetes. The total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. These factors are expected to aid the market growth in the forecast period. The diabetes care devices market is expected to be limited by the high cost of the equipment, especially in low-income countries, where the cost related to diabetes devices is very high, despite insurance coverage. For example, in the US all the expenses related to diabetes treatment, which includes diabetes care devices can reach $1,000 a month. Thus, high costs associated with diabetes care devices and their accessories are likely to impede the market growth going forward. Pharmaceutical companies are investing in developing and commercializing glucose-responsive insulins (GRIs), providing significant opportunities for the development of new types of insulin delivery devices. For example, Novo Nordisk, a Danish pharmaceutical company, has planned to develop GRIs by acquiring UK biotech start-up Ziylo with an investment of $800 million. Companies such as Eli Lily and Sanofi have also planned research projects to develop GRIs. GRIs are 'smart' insulins that automatically activate or deactivate in response to changing glucose levels in the blood. They improve diabetes treatment efficacy and reduce the incidence of hyperglycemia and hypoglycemia. Major companies in the diabetes care devices market include Abbott Laboratories, Novo Nordisk, Medtronic Inc., Dexcom, Inc., F. Hoffmann-La Roche Ltd., Becton Dickinson, Insulet, Ypsomed, ConvaTec Group Plc, and B. Braun Group. North America was the largest region in the global diabetes care devices market in 2022. Western Europe was the second largest region in the global diabetes care devices market. The regions covered in the diabetes care devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the diabetes care devices market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The diabetes care devices market consists of sales of blood glucose monitoring devices, insulin delivery devices, smart insulin pens and others that are used for monitor and treat diabetes patient. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global diabetes care devices market is segmented - 1) By Type: Blood Glucose Test Strips, Insulin Pens, Syringes, Pumps And Injectors, Lancing Devices And Equipment, Continuous Glucose Monitoring Devices And Equipment, Blood Glucose Meters 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables Subsegments Covered: Glucose Dehydrogenase, Glucose Oxidase, Pens, Injectors And Pumps, Syringes

A peristaltic pump also known as a roller pump is a positive displacement pump that moves the fluid at a constant speed regardless of the pressure at the inlet end and can be used to pump a wide range of fluids. The fluid is stored within a flexible hose or tube fitted inside the pump casing. The main types of peristaltic pumps include peristaltic tube pumps and peristaltic hose pumps. Low-pressure pumps, also known as peristaltic tube pumps, have dry casings and non-reinforced casings and use rollers to provide compressive power. The different types of products include fixed speed pumps and variable speed pumps, and the discharge capacity ranges up to 30 pounds per square inch (psi), 30-50 psi, 50-100 psi, 100-200 psi, and above 200 psi. It is implemented in various verticals such as pharmaceutical and medical, water and wastewater treatment, food and beverage, chemical processing, mining, pulp and paper and others. The peristaltic pumps market research report is one of a series of new reports from The Business Research Company that provides peristaltic pumps market statistics, including peristaltic pumps industry global market size, regional shares, competitors with a peristaltic pumps market share, detailed peristaltic pumps market segments, market trends and opportunities, and any further data you may need to thrive in the peristaltic pumps industry. This peristaltic pumps market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global peristaltic pumps market size grew from $1.51 billion in 2022 to $1.67 billion in 2023 at a compound annual growth rate (CAGR) of 10.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The peristaltic pumps market size is expected to grow to $2.48 billion in 2027 at a CAGR of 10.4%. The increasing need for wastewater treatment is expected to fuel the growth of the peristaltic pumps market in the forecast period. Wastewater treatment is the method of removing pollutants from wastewater or sewage and converting it to an effluent that can be added to the water supply with minimal environmental effects. Peristaltic pumps are the preferred pump for dosing sodium hypochlorite due to their highly accurate metered flow, which is used in wastewater treatment to destroy bacteria. Therefore, the increasing need for wastewater treatment propels the growth of the peristaltic pumps market. Technological advancements are shaping the peristaltic pumps market. Peristaltic pump manufacturing companies are focusing on developing innovative technical solutions for peristaltic pumps with increased accuracy and the ability to pump fluids at low pressures. For instance, in January 2020, a US-based Cole-Parmer Instrument Company, LLC launched Reglo Peristaltic Pump Series, built to be highly accurate low-flow (100 mL/min) models with MasterflexLive technology and compliant with 21 CFR Part 11 and EU Annex 11 regulations. The combination of features intends to provide a fluid handling experience that is connected, responsive, strong, and stable. In March 2016, Watson-Marlow Fluid Technology Group, a UK-based manufacturer of positive displacement pumps, launched 530 series peristaltic pumps for upstream and downstream bioprocessing tasks with high precession and accuracy. In September 2020, Ingersoll Rand, a US-based industrial manufacturing company, acquired Albin Pump for an undisclosed amount. This acquisition is expected to expand the technical capabilities of Ingersoll Rand in peristaltic pumps and accelerate the company's expansion into electrically powered positive displacement pumps. Albin Pump is a France-based peristaltic pump manufacturing company. Major players in the peristaltic pumps market are Watson-Marlow Fluid Technology Group, Verder Group, Cole-Parmer Instrument Company LLC, ProMinent Group, Graco Inc., Randolph Austin, IDEX Corporation, Wanner Engineering, Heidolph Instruments, Gilson Inc., Ravel Hiteks Pvt. Ltd., Albin Pumps, and WELCO Co. Ltd. Asia-Pacific was the largest region in the peristaltic pumps market in 2022. The regions covered in the peristaltic pumps market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the peristaltic pumps market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The peristaltic pumps market consists of sales of peristaltic hose pumps and peristaltic tube pumps. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global peristaltic pumps market is segmented - 1) By Type: Peristaltic Tube Pumps, Peristaltic Hose Pumps 2) By Product Type: Fixed Speed Pumps, Variable Speed Pumps 3) By Discharge Capacity: Up to 30 psi, 30-50 psi, 50-100 psi, 100-200 psi, Above 200 psi 4) By End-User: Pharmaceutical And Medical, Water And Wastewater Treatment, Food And Beverage, Chemical Processing, Mining, Pulp And Paper, Other End-Users

Cardiac assist devices and equipment are electromechanical devices that assist in pumping blood from the heart to the rest of the body. These devices are used either to partially or completely replace the function of a failing heart. The main types of cardiac assist devices and equipment are ventricular assist devices, intra-aortic balloon pumps, and the total artificial heart. Ventricular assist devices are electromechanical devices used to help with cardiac circulation. The various types of modalities are transcutaneous and implantable. These are used in hospital pharmacies, ambulatory surgical centres, and emergency services. The cardiac assist devices and equipment market research report is one of a series of new reports from The Business Research Company that provides cardiac assist devices and equipment market statistics, including cardiac assist devices and equipment industry global market size, regional shares, competitors with a cardiac assist devices and equipment market share, detailed cardiac assist devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac assist devices and equipment industry. This cardiac assist devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cardiac assist devices and equipment market size will grow from $2.15 billion in 2022 to $2.41 billion in 2023 at a compound annual growth rate (CAGR) of 12.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cardiac assist devices and equipment market size is expected to grow to $3.51 billion in 2027 at a CAGR of 9.9%. A rise in the prevalence of cardiovascular diseases increases the demand for cardiac assist devices and equipment in developed and developing economies. The increasing need for diagnosis, monitoring, early-stage treatment, and prevention of these life-threatening diseases, increase the demand for cardiac assist devices. According to the American Heart Association, by 2035, 45.1% of the US population is projected to have some form of CVD. Total costs of CVD are expected to reach $1.1 trillion in 2035, with direct medical costs projected to reach $748.7 billion and indirect costs estimated to reach $368 billion. According to the Centers for Disease Control and Prevention, anout 697,000 people died from heart diseases in 2020 which was almost 1 in every 5 deaths. Risks associated with the implantation of cardiac assist devices into the human body acts as a major restraint for the growth of this market. Risks associated with device implantation include respiratory failure, blood clot formation, occurrences of stroke, and the risk of device failure leading to a heart attack are some major reasons due to which people are hesitant to adopt cardiac assist devices, thus the demand from end-users of cardiac assist devices remains restrained, therefore limiting the growth prospects of the market. The infection rate of cardiac implantable electronic devices is 1.7% initially after implantation, whereas after 2years the infection rate is 9.5%, increasing the risk factor. The rising number of device replacements results in complex procedures, considerable risks with an increase in infection rates. Device miniaturization is becoming popular in the cardiac assist devices and equipment market. The concept of minimizing the size of the cardiac assist devices enhances device implantation, provides potentially shorter hospital stay through the use of less invasive surgery such as 'Thoracotomy'. Cardiac assist device miniaturization acts as a replacement to heart transplantation as destination therapy, due to lack of heart donors. For instance, Heartware Ltd. is increasingly investing in the Heartware's device miniaturization program, aiming to reduce the weight, size, and energy consumption of the device. Furthermore, the United Kingdom National Health Service has invested in a Bridge to Transplant program (BTT) where the performance of two minimally invasive cardiac assist devices was compared, out of which the best one was found based on better clinical outcome and more cost-effectiveness due to its miniaturized design. In June 2021, Medtronic PLC., an Irish medical device company, stopped the sale and distribution of the HeartWare Ventricular Assist Devices system due to the risk of mortality and neurological adverse events due to the use of the device and malfunctioning in the starting of the device. Major players in the cardiac assist devices and equipment market are Abbot Laboratories, Berlin Heart GmbH, Abiomed Inc., Bivacor Pvt Ltd., Calon Cardio - Technology Ltd., Cardiobridge GmbH, Balton Sp. Z O.O, Cardiac Assist Inc., Braile Biomedica Ltd., and Circulate Inc. North America was the largest region in global cardiac assist devices and equipment market in 2022. Western Europe was the second-largest region in cardiac assist devices and equipment market. The regions covered in global cardiac assist devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cardiac assist devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, USA, and Australia. The cardiac assist devices and equipment market consist of sales of ventricular assist devices (LVAD), intra-aortic balloon pumps, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cardiac assist devices and equipment market is segmented - 1) By Type: Ventricular Assist Devices (LVAD), Intra-Aotic Baloon Pumps, Total Artificial Heart 2) By Application: Hospital Pharmacies, Ambulatory Surgical Centres, Emergency Services 3) By Modality: Transcutaneous, Implantable